CHINA BIOTECH SERVICES HOLDINGS LIMITED 中國生物科技服務控股有限公司 （於開曼群島註冊成立並在百慕達繼續營業之有限公司） （股份代號：8037） 截至二零二三年九月三十日止九個月 之第三季度業績公告 香港聯合交易所有限公司（「聯交所」）GEM的特色 GEM的定位，乃為中小型公司提供一個上市的市場，此等公司相比起其他在主板 上市的公司帶有較高投資風險。有意投資的人士應了解投資於該等公司的潛在風 險，並應經過審慎周詳的考慮後方作出投資決定。 由於GEM上市公司普遍為中小型公司，在GEM買賣的證券可能會較於主板買賣 之證券承受較大的市場波動風險，同時無法保證在GEM買賣的證券會有高流通量 的市場。 香港交易及結算所有限公司及聯交所對本公告之內容概不負責，對其準確性或完 整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生 或因倚賴該等內容而引致之任何損失承擔任何責任。 本公告的資料乃遵照《GEM證券上市規則》（「GEM上市規則」）而刊載，旨在提供 有關中國生物科技服務控股有限公司（「本公司」）的資料；本公司的董事（「董事」） 願就本公告的資料共同及個別地承擔 ...

Financial Performance - The net cash generated from operating activities for the six months ended June 30, 2023, was HKD 310,855,000, compared to HKD 184,025,000 for the same period in 2022, representing an increase of 68.8%[8]. - Revenue from medical laboratory testing and health check services for the six months ended June 30, 2023, was HKD 170,525,000, down 63.0% from HKD 460,906,000 in the same period of 2022[17]. - Revenue from the sale and distribution of health-related and pharmaceutical products decreased by 83.5% to HKD 356,000 from HKD 215,402,000 year-on-year[17]. - The group’s revenue for the six months ended June 30, 2023, was approximately HKD 182,357,000, a significant decrease of about 73.45% compared to approximately HKD 686,909,000 for the same period in 2022[107]. - The gross profit for the first half of 2023 was approximately HKD 61,326,000, a decrease of about HKD 293,578,000 compared to approximately HKD 354,904,000 in the first half of 2022, with a gross margin of 33.63%, down 18.04 percentage points from 51.67%[116]. - The company recorded a net loss attributable to shareholders of approximately HKD 30,484,000 for the first half of 2023, a significant decline from a net profit of HKD 68,220,000 in the same period of 2022[142]. Cash and Liquidity - The total cash and cash equivalents at the end of the period was HKD 245,396,000, up from HKD 204,884,000 in the previous year, reflecting a growth of 19.7%[8]. - The company reported a net cash outflow from investing activities of HKD 144,737,000, compared to HKD 122,600,000 in the previous year, indicating increased investment expenditures[8]. - As of June 30, 2023, the cash and bank balance was approximately HKD 245,396,000, an increase of about HKD 152,626,000 from HKD 92,770,000 on December 31, 2022[151]. - The company’s liquidity ratio improved to 2.14 times as of June 30, 2023, compared to 1.61 times at the end of 2022[130]. Equity and Liabilities - The total equity attributable to owners of the company decreased to HKD 544,374,000 from HKD 602,675,000, a decline of 9.7%[1]. - The total liabilities increased significantly, with current liabilities rising to HKD 172,585,000 from HKD 548,664,000, indicating a substantial change in the company's financial position[1]. - The total equity and liabilities amounted to HKD 904,083,000, down from HKD 1,470,491,000, reflecting a significant reduction in the company's overall financial structure[1]. - The company’s debt-to-asset ratio improved to approximately 27.34% as of June 30, 2023, compared to 43.79% at the end of 2022[130]. Investments and Capital Expenditures - The company has capital commitments of approximately HKD 235.99 million as of June 30, 2023, compared to HKD 237.54 million as of December 31, 2022[71]. - The company has entered into an agreement with Sumitomo for technical advisory services related to the installation and commissioning of boron neutron capture therapy equipment, with a service fee of approximately HKD 21.66 million[72]. - The company has entered into agreements to purchase boron neutron capture therapy equipment and drugs, aiming to be the first provider of this treatment in Greater China[126]. - The investment in boron neutron capture therapy projects has utilized approximately HKD 23,340,000, with a remaining balance of HKD 22,246,000 as of June 30, 2023[155]. Employee Costs and Compensation - Employee costs, including salaries and bonuses, decreased to HKD 19,562,000 for the three months ended June 30, 2023, down 33.1% from HKD 29,183,000 in the same period of 2022[24]. - The total employee cost for the first half of 2023 was approximately HKD 51,621,000, down from HKD 59,941,000 in the same period of 2022[163]. - The company recorded a total compensation for key management personnel of HKD 4,575,000 for the six months ended June 30, 2023, compared to HKD 4,869,000 for the same period in 2022[105]. Business Operations and Strategy - The company is committed to building and operating a cancer treatment center in Hainan, utilizing a boron neutron capture therapy system, with a medical institution practice license granted for five years until December 2027[112][113]. - The company has established laboratory testing service agreements with nine out of eighteen designated regional health center operators in Hong Kong to expand its health screening services[123]. - The company has launched several new tests, including HPV DNA tests and colorectal cancer DNA tests, to meet anticipated demand[124]. - The company is seeking collaborations with hospitals and clinical laboratories to expand its next-generation sequencing (NGS) testing services[125]. Share Capital and Stock Options - The total number of issued shares of the company was 963,231,150, with a par value of HKD 0.10 per share[169]. - The company has issued stock options for up to 5,000,000 shares, representing approximately 0.52% of the total issued shares as of January 6, 2023[144]. - The company has a stock option plan adopted to reward eligible participants for their contributions to the group's success[174]. - The stock options granted in August 2019 have an exercise price ranging from HKD 2.00 to HKD 2.20, with a total of 3,335,000 options available[200].

CHINA BIOTECH SERVICES HOLDINGS LIMITED 中國生物科技服務控股有限公司 （於開曼群島註冊成立並在百慕達繼續營業之有限公司） （股份代號：8037） 截至二零二三年六月三十日止六個月 中期業績公告 香港聯合交易所有限公司（「聯交所」）GEM的特色 GEM的定位，乃為中小型公司提供一個上市的市場，此等公司相比起其他在主板 上市的公司帶有較高投資風險。有意投資的人士應了解投資於該等公司的潛在風 險，並應經過審慎周詳的考慮後方作出投資決定。 由於GEM上市公司普遍為中小型公司，在GEM買賣的證券可能會較於主板買賣 之證券承受較大的市場波動風險，同時無法保證在GEM買賣的證券會有高流通量 的市場。 香港交易及結算所有限公司及聯交所對本公告之內容概不負責，對其準確性或完 整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生 或因倚賴該等內容而引致之任何損失承擔任何責任。 本公告的資料乃遵照《GEM證券上市規則》（「GEM上市規則」）而刊載，旨在提供 有關中國生物科技服務控股有限公司（「本公司」）的資料；本公司的董事（「董事」） 願就本公告的資料共同及個別地承擔全部責 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何 部分內容而產生或因倚賴該等內容而引致之任何損失承擔任何責任。 CHINA BIOTECH SERVICES HOLDINGS LIMITED 中國生物科技服務控股有限公司 （於開曼群島註冊成立並在百慕達繼續營業之有限公司） （股份代號：8037） 補充公告 有關截至二零二二年十二月三十一日止年度之年報的 進一步資料 謹此提述中國生物科技服務控股有限公司（「本公司」）於二零二三年三月二十九日 所刊發截至二零二二年十二月三十一日止年度之年報（「年報」）。除另有說明者外， 於本公告內所採用之詞彙與年報內所界定者具有相同涵義。 除於年報內所披露的資料外，本公司謹此提供以下資料： 第18頁之表格內（修改內容以底劃線顯示）： 截至 於 二零二二年 二零二二年 十二月 十二月 所得款項 ...

Revenue Performance - The insurance brokerage segment's revenue decreased from approximately HKD 3,460,000 in Q1 2022 to about HKD 1,192,000 in Q1 2023, a decline of 65.55% due to intense market competition [1]. - The logistics services segment's revenue fell from approximately HKD 3,199,000 in Q1 2022 to about HKD 2,000 in Q1 2023, a significant drop of 99.94% attributed to reduced demand for testing supplies and sample logistics services [4]. - Total revenue for the first quarter of 2023 was HKD 130,561 thousand, a decrease of 65.9% compared to HKD 384,157 thousand in the same period of 2022 [37]. - For the three months ended March 31, 2023, revenue from medical laboratory testing and health check services was HKD 129,065 thousand, a decrease of 20.6% compared to HKD 162,662 thousand in the same period of 2022 [54]. - Revenue from the sale and distribution of health-related and pharmaceutical products was HKD 302 thousand, down significantly from HKD 214,752 thousand year-on-year [54]. - The sales and distribution segment for healthcare and pharmaceutical products saw a significant revenue drop from approximately HKD 214,752,000 in Q1 2022 to about HKD 302,000 in Q1 2023, a decrease of approximately 99.86% [101]. - The decline in revenue was attributed to reduced demand for rapid antigen test kits following the relaxation of COVID-19 quarantine regulations [101]. Profitability and Loss - The group recorded a gross profit of approximately HKD 49,161,000 in Q1 2023, down about HKD 140,571,000 from HKD 189,732,000 in Q1 2022, with a gross profit margin of 37.65%, a decrease of 11.75 percentage points year-on-year [6]. - The company reported a net loss attributable to shareholders of approximately HKD 15,375,000 in Q1 2023, compared to a net profit of HKD 34,938,000 in Q1 2022, mainly due to decreased demand for COVID-19 testing services [10]. - The company reported an operating loss of HKD 1,091 thousand for the first quarter of 2023, compared to an operating profit of HKD 133,261 thousand in the same period last year [37]. - The net loss for the period was HKD 7,781 thousand, a stark contrast to a profit of HKD 106,585 thousand in the first quarter of 2022 [37]. - The company reported a loss attributable to owners of the company of HKD 15,375,000 for the first quarter of 2023, compared to a profit of HKD 34,938,000 in the first quarter of 2022 [75]. - The total comprehensive loss for the period was HKD 28,892 thousand, compared to a total comprehensive income of HKD 6,048 thousand in the same period of 2022 [54]. Expenses and Costs - Administrative expenses were approximately HKD 44,717,000 in Q1 2023, a decrease of about HKD 9,623,000 or 17.71% compared to HKD 54,340,000 in Q1 2022, primarily due to reduced research and development costs [8]. - Financing costs increased to approximately HKD 1,353,000 in Q1 2023 from HKD 1,217,000 in Q1 2022, primarily due to costs associated with convertible bonds issued [9]. - Sales and distribution expenses were approximately HKD 3,720,000 in Q1 2023, a slight decrease of about HKD 185,000 or 4.74% from HKD 3,905,000 in Q1 2022, maintaining a stable level [7]. Strategic Initiatives and Future Outlook - The company entered into a total supply agreement with BGI Genomics for a maximum annual transaction limit of HKD 120,000,000, effective from January 18, 2023 [11]. - The company has committed a total of HKD 1.9 billion for the development of community health centers, expecting regular government funding to support future operations [16]. - The company anticipates continued growth in demand for health check and related medical services in Hong Kong due to increased public health awareness and an aging population [16]. - The company is actively seeking partnerships with various medical platforms and insurance companies to expand its healthcare services in the Greater Bay Area [18]. - New tests, including HPV DNA tests and colorectal cancer DNA tests, have been launched to meet anticipated demand [18]. - The company is preparing for FDA testing product validation in collaboration with hospitals and surgeons, aiming to enhance personalized precision health services [18]. - The company aims to leverage advancements in biomedical research and technology to develop innovative solutions for precision diagnosis and treatment [26]. - The company is focusing on expanding its cancer diagnostic and treatment platform, although specific future projections were not detailed in the report [41]. - The company continues to explore new product development and market expansion strategies to enhance its service offerings in the biotechnology sector [41]. - The company aims to expand its healthcare product offerings through strategic partnerships and new product introductions [101]. Corporate Governance and Compliance - The company complied with the GEM Listing Rules and corporate governance code during the first quarter of 2023 [139]. - The board has established an audit committee to comply with GEM Listing Rules 5.28 and 5.29, consisting of three independent non-executive directors [140]. - The board emphasizes the importance of corporate governance and is committed to maintaining high standards and compliance with legal and regulatory requirements [150]. - The company confirmed that all directors complied with the trading standards and the code of conduct for securities trading during the first quarter of 2023 [149]. - The company has maintained the public float as specified by the GEM Listing Rules as of the report date [152]. - The board consists of four executive directors and three independent non-executive directors, ensuring a balanced governance structure [142]. Shareholder Information - As of March 31, 2023, the total issued shares of the company amounted to 963,231,150 ordinary shares [110]. - Major shareholder Genius Earn holds approximately 54.97% of the company's shares, totaling 529,500,546 shares [109]. - The company has a total of 96,323,115 shares available for issuance under the share incentive plan, representing 10% of the total issued shares as of the plan's adoption date [132]. - The share incentive plan has a remaining term of 10 years, expiring on August 17, 2031 [136]. - The company granted stock options to three directors on August 20, 2019, September 2, 2020, and January 6, 2023 [136]. - The total number of stock options exercisable during the first quarter of 2023 was 11,760,000 [130]. - The company did not purchase, sell, or redeem any listed securities during the first quarter of 2023 [137]. - The company has not established any arrangements for directors to benefit from acquiring shares or debt securities of the company or any other entity during the first quarter of 2023 [136].

CHINA BIOTECH SERVICES HOLDINGS LIMITED 中國生物科技服務控股有限公司 （於開曼群島註冊成立並在百慕達繼續營業之有限公司） （股份代號：8037） 截至二零二三年三月三十一日止三個月 之第一季度業績公告 香港聯合交易所有限公司（「聯交所」）GEM的特色 GEM的定位，乃為中小型公司提供一個上市的市場，此等公司相比起其他在主板 上市的公司帶有較高投資風險。有意投資的人士應了解投資於該等公司的潛在風 險，並應經過審慎周詳的考慮後方作出投資決定。 由於GEM上市公司普遍為中小型公司，在GEM買賣的證券可能會較於主板買賣 之證券承受較大的市場波動風險，同時無法保證在GEM買賣的證券會有高流通量 的市場。 香港交易及結算所有限公司及聯交所對本公告之內容概不負責，對其準確性或完 整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生 或因倚賴該等內容而引致之任何損失承擔任何責任。 本公告的資料乃遵照《GEM證券上市規則》（「GEM上市規則」）而刊載，旨在提供 有關中國生物科技服務控股有限公司（「本公司」）的資料；本公司的董事（「董事」） 願就本公告的資料共同及個別地承 ...

Financial Performance - The total revenue for the year ended December 31, 2022, was approximately HKD 1,851,532,000, representing a significant increase of over 197% compared to the previous year[8]. - Gross profit for the same period was approximately HKD 1,100,957,000, reflecting a year-on-year growth of 208%, with a gross margin of 59.46% (up from 57.40% in the previous year)[8]. - The company reported record revenue and profit during the fiscal year due to high demand for nucleic acid testing services amid the COVID-19 pandemic[48]. - The net profit attributable to the company's owners increased significantly to approximately HKD 258,087,000 in 2022 from HKD 19,385,000 in 2021, driven by high demand for COVID-19 testing services[175]. - Revenue from the medical laboratory testing and health check services increased from approximately HKD 607,776,000 in 2021 to approximately HKD 1,619,568,000 in 2022, representing a 166% increase[163]. COVID-19 Testing Services - The company completed over 10,000,000 COVID-19 nucleic acid tests during the year, an increase of over 183% compared to 3,600,000 tests completed in the previous year[13]. - The demand for medical laboratory testing services and health check services, including COVID-19 nucleic acid testing, remained high due to ongoing COVID-19 outbreaks[155]. - The company became one of the designated service providers for COVID-19 rapid nucleic acid testing at Shenzhen Bay Port and Hong Kong-Zhuhai-Macao Bridge Hong Kong Port for travelers leaving Hong Kong[155]. - The company provided over 15,000,000 COVID-19 nucleic acid tests during the pandemic, supporting the Hong Kong government's community testing initiatives[160]. Business Expansion and New Services - The company launched new medical laboratory testing and health check services, including pre-vaccination health checks and cancer screening tests, to enhance competitiveness in the post-pandemic era[14]. - The company has established six service agreements with regional health center operators to provide laboratory testing services for various diseases, including diabetes and colorectal cancer[15]. - A high-standard molecular biology laboratory has been established in collaboration with Pillar Biosciences, Inc. to enhance precision diagnostic testing services[15]. - The company aims to achieve further breakthroughs in business performance through the commercialization of a range of medical laboratory testing and healthcare services in the coming years[2]. - The company is focusing on restoring non-COVID-19 medical diagnostic and treatment services as the pandemic subsides[48]. Environmental Commitment - The company is committed to reducing its environmental footprint through sustainable practices in R&D, medical testing, and precision cancer diagnostics[73]. - The total greenhouse gas emissions related to the company's operations during the reporting period were estimated at 11,040 tons of CO2 equivalent, primarily due to increased business activities and higher electricity consumption[87]. - The company aims to reduce greenhouse gas emissions as part of its long-term environmental goals[126]. - The company has established an ESG committee to monitor progress and develop strategies to achieve ESG goals, recognizing the importance of ESG considerations for long-term success[73]. - The company has set policies to ensure compliance with all applicable environmental laws and regulations, fostering an environmentally conscious culture among employees[74]. Research and Development - Significant progress has been made in the research and development of immune cell therapy, with clinical trials for investigational new drugs currently underway[48]. - The company received approval for its investigational new drug (IND) application for LY007, a CAR-T therapy product, marking a significant milestone in its oncology treatment offerings[166]. - The company is seeking collaborations with contract research organizations and local hospitals for next-generation sequencing (NGS) cancer diagnostic tests[161]. Capital and Financing - The company issued convertible bonds totaling USD 10,000,000, equivalent to approximately HKD 77,800,000, with a conversion price of HKD 1.45 per share[125]. - The net proceeds from the convertible bonds are allocated as follows: HKD 23,340,000 for investment in boron neutron capture therapy projects and HKD 15,124,000 for R&D costs and general operating funds[125]. - The company entered a five-year exclusive distribution agreement for NMN products, allowing distribution rights in regions including Hong Kong, Macau, and several Southeast Asian countries[39]. Waste Management and Compliance - The group has established strict policies for the management of medical waste to ensure proper disposal[90]. - The company has implemented strict health and safety measures during the COVID-19 pandemic to ensure employee safety and minimize virus transmission[180]. - The company aims to maintain a zero-violation record in hazardous waste management, reflecting its commitment to compliance and safety standards[183]. - The company has not recorded any violations of environmental laws during the reporting period[128]. Employee and Operational Metrics - The total number of full-time employees was 260, with an overall turnover rate of 32% during the reporting period[140]. - The turnover rate for part-time employees was 18%, with 17 part-time employees reported[141]. - The employee turnover rate for males was 30% and for females was 31%[141]. - The turnover rate for employees under 30 years old was 35%, while it was 27% for those aged 30 to 50, and 31% for those over 50[141].

CHINA BIOTECH SERVICES HOLDINGS LIMITED 中國生物科技服務控股有限公司 （於開曼群島註冊成立並在百慕達繼續營業之有限公司） （股份代號：8037） 截至二零二二年十二月三十一日止年度 全年業績公告 香港聯合交易所有限公司（「聯交所」）GEM的特色 GEM的定位，乃為中小型公司提供一個上市的市場，此等公司相比起其他在主板 上市的公司帶有較高投資風險。有意投資的人士應了解投資於該等公司的潛在風險， 並應經過審慎周詳的考慮後方作出投資決定。 由於GEM上市公司普遍為中小型公司，在GEM買賣的證券可能會較於主板買賣之 證券承受較大的市場波動風險，同時無法保證在GEM買賣的證券會有高流通量的 市場。 香港交易及結算所有限公司及聯交所對本公告之內容概不負責，對其準確性或完 整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或 因倚賴該等內容而引致之任何損失承擔任何責任。 本公告的資料乃遵照《GEM證券上市規則》（「GEM上市規則」）而刊載，旨在提供 有關中國生物科技服務控股有限公司（「本公司」）的資料；本公司的董事（「董事」） 願就本公告的資料共同及個別地承擔全部 ...

CHINA BIOTECH SERVICES HOLDINGS LIMITED 中國生物科技服務控股有限公司 (Incorporated in the Cayman Islands and continued in Bermuda with limited liability) Stock Code: 8037 Precision Treatment 精準治療 Precision Diagnosis 精準檢測 Future Biotechnology Platform 未來生物科技平臺 THIRD QUARTERLY REPORT 2022 CHINA BIOTECH SERVICES HOLDINGS LIMITED 中國生物科技服務控股有限公司 (於開曼群島註冊成立並在百慕達繼續營業之有限公司) 股份代號: 8037 Precision Treatment 精準治療 Precision Diagnosis 精準檢測 Future Biotechnology Platform 未來生物科技平臺 第三季度業績報 告 2022 01 香港聯合交易所有限公司（「聯交所」）GEM的特色 GEM的定位，乃為中小型公司 ...

CHINA BIOTECH SERVICES HOLDINGS LIMITED 中國生物科技服務控股有限公司 (於開曼群島註冊成立並在百慕達繼續營業之有限公司) 股份代號: 8037 Precision Diagnosis 精準檢測 Future Biotechnology Platform 未來生物科技平臺 Precision Treatment 精準治療 中期報告 2022 香港聯合交易所有限公司（「聯交所」）GEM的特色 GEM的定位，乃為中小型公司提供一個上市的市場，此等公司相比起其他在主板上市的公司帶有 較高投資風險。有意投資的人士應了解投資於該等公司的潛在風險，並應經過審慎周詳的考慮後 方作出投資決定。 由於GEM上市公司普遍為中小型公司，在GEM買賣的證券可能會較於主板買賣之證券承受較大的 市場波動風險，同時無法保證在GEM買賣的證券會有高流通量的市場。 香港交易及結算所有限公司及聯交所對本報告之內容概不負責，對其準確性或完整性亦不發表任 何聲明，並明確表示概不就因本報告全部或任何部分內容而產生或因倚賴該等內容而引致之任何 損失承擔任何責任。 本報告的資料乃遵照《GEM證券上市規則》（「GEM上 ...